It will also be important to ascertain the optimal treatment targets and the most suitable BP-lowering strategy (ideally by head-to-head comparison of SGLT-2 inhibitors and the newest GLP-1-based therapies) in a sizeable, high-risk group of hypertensive patients with obesity and diabetes. The gene discussed is GLP1R; the disease is Obesity.